- Home
- TLN vs RVMD Comparison
TLN vs RVMD Comparison
Compare TLN & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLN
- RVMD
- Stock Information
- Founded
- TLN 2015
- RVMD 2014
- Country
- TLN United States
- RVMD United States
- Employees
- TLN N/A
- RVMD N/A
- Industry
- TLN Electric Utilities: Central
- RVMD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TLN Utilities
- RVMD Health Care
- Exchange
- TLN Nasdaq
- RVMD Nasdaq
- Market Cap
- TLN 8.1B
- RVMD 8.7B
- IPO Year
- TLN N/A
- RVMD 2020
- Fundamental
- Price
- TLN $217.08
- RVMD $37.92
- Analyst Decision
- TLN Strong Buy
- RVMD Strong Buy
- Analyst Count
- TLN 11
- RVMD 13
- Target Price
- TLN $242.55
- RVMD $67.77
- AVG Volume (30 Days)
- TLN 1.6M
- RVMD 1.4M
- Earning Date
- TLN 02-27-2025
- RVMD 05-07-2025
- Dividend Yield
- TLN N/A
- RVMD N/A
- EPS Growth
- TLN 681.86
- RVMD N/A
- EPS
- TLN 17.67
- RVMD N/A
- Revenue
- TLN $2,073,000,000.00
- RVMD N/A
- Revenue This Year
- TLN $9.02
- RVMD N/A
- Revenue Next Year
- TLN $20.04
- RVMD $153.09
- P/E Ratio
- TLN $12.33
- RVMD N/A
- Revenue Growth
- TLN N/A
- RVMD N/A
- 52 Week Low
- TLN $98.50
- RVMD $29.55
- 52 Week High
- TLN $258.03
- RVMD $62.40
- Technical
- Relative Strength Index (RSI)
- TLN 55.98
- RVMD 46.02
- Support Level
- TLN $198.18
- RVMD $37.61
- Resistance Level
- TLN $211.37
- RVMD $39.59
- Average True Range (ATR)
- TLN 10.99
- RVMD 1.48
- MACD
- TLN 4.07
- RVMD 0.13
- Stochastic Oscillator
- TLN 97.55
- RVMD 57.01
About TLN Talen Energy Corporation Common Stock
Talen Energy Corp is an independent power producer and energy infrastructure company. The company owns and operates approximately 10.7 gigawatts of power infrastructure in the United States. The group produces and sells electricity, capacity, and ancillary services into wholesale U.S. power markets, including PJM and WECC, with its generation fleet located in the Mid-Atlantic and Montana.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.